NPC at AMCP 2025 Annual Meeting
Members of the NPC team will participate in sessions and present research findings.
Check Out the Recap & Highlights
Learn more about NPC's presence at #AMCP2025 and the policy-relevant research the team presented.
Join NPC at AMCP 2025 in Houston, TX!
NPC's research and leadership team will be attending and presenting at #AMCP2025, March 31 - April 3, 2025 in Houston, Texas. Learn more in the details below and check back soon for the latest updates.
Education Session
Patient Engagement in Managed Care Pharmacy: Putting Policy into Practice
Tuesday, April 1 | 10:30 – 11:45 AM CT
Moderator:
Kimberly Westrich, MA, Chief Strategy Officer, National Pharmaceutical Council
Faculty:
- Kimberly Lenz, PharmD, MBA, FAMCP, Chief Pharmacy Officer, MassHealth, Massachusetts Medicaid
- Emily G. Tsiao, PharmD, BCPS, Medical Policies Clinical Pharmacist, Premera Blue Cross
- Joe Vandigo, PhD, Principal Scientist & Director of Value, Applied Patient Experience
As healthcare decision-making becomes more patient-centric, incorporating patient perspectives is critical for developing meaningful formulary design models. New CMS regulations will require patient representation on P&T committees for plans offering essential health benefits and expand beneficiary engagement across state Medicaid agencies. But will these efforts be sufficient? Informative? If not, what practical actions are needed to ensure that the experience patients and beneficiaries bring can be translated into meaningful and actionable insights? Hear examples from experts that will support individual patients tasked with representing diverse patient populations and health conditions; pair committee membership with more representative, rigorous, and robust patient experience information; and identify policies, processes, and partnerships needed. Together, these practices can shift patient centricity from representation to informative, meaningful, and actionable guidance. Pharmacy directors representing a commercial health plan and state Medicaid agency will offer their experiences to help turn policies to increase patient-centricity into practice.
Education Session
Inflation Reduction Act Ripple Effects: Considerations for Patient Access and 340B
Tuesday, April 1 | 1:30 - 2:45 PM CT
Faculty:
- Michael Einodshofer, RPh, President, MERx Consulting, LLC
- Julie Patterson, PharmD, PhD, Senior Director of Research, National Pharmaceutical Council
- William Sarraille, Adjunct Professor, University of Maryland Francis King Carey School of Law
- Cynthia Pigg, Pigg Insights
The Inflation Reduction Act (IRA) will create a ripple effect across Medicare Part D formulary design, impacting multiple key stakeholders. It is critical to understand potential unintended consequences of the IRA on these stakeholders, including patients, PBMs and health plans, and 340B covered entities. What does research evidence tell us about existing Part D access to Drug Price Negotiation Program (DPNP)-selected drugs and therapeutic alternatives? How will changing incentives amidst the IRA affect PBMs and health plans, and what will this mean for their business model and formulary design decisions? What will it mean for 340B covered entities and patients? This session will explore the changing incentives in formulary structure and drug utilization as IRA implementation proceeds, with an eye toward patient access. Current research on access to DPNP-selected drugs and 2025 Part D formularies, as well as anticipated trends and impacts on healthcare stakeholders, will be discussed.
Student & New Practitioner Networking Reception
Tuesday, April 1 | 5:30 PM - 6:30 PM CT
Join the NPC team at Xochi, a chic Oaxacan-inspired restaurant at the Marriott Marquis, for the AMCP 2025 Student & New Practitioner Networking Reception! NPC is proud to sponsor this reception to offer students and early career professionals an opportunity to network with established experts in the field who will share advice, career opportunities, and life experiences.
Poster Session
Orphan Oncology Drug Development: Implications for the Inflation Reduction Act’s Orphan Drug Exclusion
Wednesday, April 2 | 11:30 AM – 12:45 PM CT
NPC Presenter and Co-author: James Motyka, PharmD
Poster Session
Subsequent Indications in Personalized Medicine: Potential Implications of the Drug Price Negotiation Program on Clinical Development
Wednesday, April 2 | 11:30 AM – 12:45 PM CT
NPC Presenter and Co-authors: Tyler D. Wagner, PharmD, PhD; Haley McKeefer, PharmD, MHA, MS
Education Session
Understanding 340B Stakeholder Perspectives, Litigation Trends, and Reform Prospects
Wednesday, April 2 | 4:15 PM - 5:30 PM CT
Faculty:
- Alan Arville, Attorney, Epstein Becker Green
- John M. O'Brien, PharmD, MPH, President & CEO, National Pharmaceutical Council
- Ted Slafsky, Publisher and CEO, 340B Report
- Melissa Andel, Principal Consultant, CommonHealth Solutions
The 340B drug pricing program remains a complex and evolving issue, impacting a wide range of stakeholders across the healthcare landscape. This session will provide an overview of how the program operates and its impact on key stakeholders, including covered entities, contract pharmacies, and payers. Faculty will explore the evolving legal landscape, examining how ongoing litigation has become the primary driver of policy changes in the absence of clear regulatory authority. The session will also involve discussion surrounding the prospects for administrative or legislative reform, considering recent proposals and the political and practical challenges ahead. Attendees will leave with a deeper understanding of the program’s current challenges and future trajectory.